By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Shionogi & Co., Ltd. 

1-8, Doshomachi 3-Chome
Osaka     541-0045  Japan
Phone: 81-0-6-6202-2161 Fax: 81-0-6-6229-9596



Company News
Shionogi Announces Positive Top-Line Results For S-033188 Phase III Study (CAPSTONE-1) In Otherwise Healthy Influenza Patients 7/24/2017 6:22:32 AM
Shionogi Release: Further Evidence Supports Cefiderocol Activity Against MDR Gram-Negative Pathogens: Data Presented At The American Society For Microbiology Microbe (ASM) Meeting 6/1/2017 9:32:43 AM
Shionogi Presents New Data On Cefiderocol (S-649266), A Siderophore Cephalosporin, And S-033188 A Cap-Dependent Endonuclease Inhibitor For Treatment Of Influenza At ECCMID 2017 4/18/2017 7:34:27 AM
Shionogi Release: FDA Approves Symproic (Naldemedine) Once-Daily Tablets C-II For The Treatment Of Opioid-Induced Constipation In Adults With Chronic Non-Cancer Pain 3/24/2017 6:25:48 AM
Duchesnay Expands Its Women's Health Product Portfolio With Acquisition Of Osphena From Shionogi 3/13/2017 8:25:22 AM
Shionogi Release: Pharma's Investigators are Prepping a FDA App for New Antibiotic After Positive Trial 1/13/2017 6:16:26 AM
Shionogi Release: Pharma Announces Positive Top-Line Results For Cefiderocol Pivotal cUTI Clinical Trial 1/12/2017 6:23:04 AM
Shionogi And Purdue Pharma L.P. Establish Alliance For Joint U.S. Commercialization Of Naldemedine 12/19/2016 10:01:55 AM
Shionogi Release: Cefiderocol, A Novel Investigational Siderophore Cephalosporin, Demonstrated Potent Activity Against Multi-Drug Resistant Gram-Negative Pathogens 10/26/2016 7:51:31 AM
Shionogi Release: Naldemedine Phase III Study Demonstrates Long-Term Safety And Efficacy For The Treatment Of Opioid-Induced Constipation 9/7/2016 3:09:38 PM